EndoToxin.com
Title
Endacea Home Page
Description
Excerpted from the website:
- adenosine receptor antagonists. The lead compound, L-97-1, is being developed for the prevention and early treatment of asthma with a dual mechanism of action: prevention of both bronchoconstriction and inflammation. Endacea believes that this oral monotherapy will compete favorably with current market leaders, reducing or eliminating the need for inhaled steroids. Other indications for L-97-1 or a follow-on molecule from Endacea's recent composition of matter patents include allergic rhinitis, chronic obstructive pulmonary disease, and acute decompensated heart failure with impaired renal function.
Languages
English
